Main Article Content

Mohammed Hasan Naji Albaldawi, Zaid Ali Abd Ali


Post-COVID fibrosis has emerged as a significant concern among survivors, characterized by persistent respiratory symptoms and progressive lung damage. Pirfenidone, an antifibrotic agent, has shown promise in treating various fibrotic lung diseases. This review examines the therapeutic potential of Pirfenidone in managing post-COVID fibrosis based on current literature and clinical studies. We discuss its mechanism of action, pharmacokinetics, safety profile, and clinical efficacy. Additionally, we explore its role in mitigating pulmonary fibrosis, reducing inflammation, and improving lung function in post-COVID patients. The review also addresses potential challenges, such as optimal dosage, duration of treatment, and long-term outcomes. Overall, Pirfenidone holds promise as a therapeutic option for post-COVID fibrosis, but further research is warranted to elucidate its efficacy and safety in this specific population.

Article Details

How to Cite
Zaid Ali Abd Ali, M. H. N. A. (2024). PIRFENIDONE FOR POST-COVID FIBROSIS TREATMENT. Obstetrics and Gynaecology Forum, 34(3s), 851–860. Retrieved from http://obstetricsandgynaecologyforum.com/index.php/ogf/article/view/371